Answers are grounded in this paper and cite their sources.
Pelvic inflammatory disease (PID) remains one of the leading causes of chronic pelvic pain, pelvic adhesions, chronic endometritis, tubal-peritoneal infertility and reproductive losses. This resolution summarizes the outcomes of the Expert Council meeting held on July 2, 2026, in Saint Petersburg within the XIX Regional Scientific and Educational Forum "Mother and Child" and presents an interdisciplinary consensus on the pathogenetic therapy of PID. The experts reviewed current data on the epidemiology and polymicrobial etiology of PID, the role of biofilms in infection persistence and reduced efficacy of antibacterial therapy, and the mechanisms underlying chronic endometritis, fibrosis and adhesion formation. Experimental in vivo and in vitro data on the antifibrotic, anti-inflammatory and antibiofilm effects of bovhyaluronidase azoximer were analyzed, together with a systematic review and meta-analysis of 26 controlled clinical trials (n=2111) that demonstrated higher rates of pelvic pain resolution, pathogen elimination, relapse-free course and pregnancy when the drug was added to standard therapy. The experts concluded that antibacterial therapy remains the mandatory basic component of PID treatment, whereas bovhyaluronidase azoximer may be considered a pathogenetically justified component of complex therapy in patients with a clinically significant inflammatory-fibrotic and adhesive component of the disease, within its approved indications. Recommendations for clinical practice, research and medical education are proposed.
No takes yet. Share an insight, caveat, or question.
Sukhikh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: